Navigation Links
Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference
Date:9/30/2009

---------------------- % HbA1c at baseline 7.67 7.90 7.45 7.38 -------------------------------------------------------------------------- % HbA1c at end of treatment 7.15 7.28 7.00 6.80 -------------------------------------------------------------------------- Change from baseline -0.54* -0.62* -0.45* -0.73* -------------------------------------------------------------------------- Mean change in weight (kg) -0.27 -0.28 -1.13 -3.09* -------------------------------------------------------------------------- *p = < 0.05

Although the treatment duration in the study was only 28 days, decreases in HbA1c and body weight were observed across all dose arms. Changes in HbA1c from baseline were statistically significant across all treatment arms. The most commonly reported adverse events were nausea and vomiting which were mostly mild, transient, dose dependent and limited to the first week of therapy.

"We've been very pleased with the positive results of this study and rapid progress in the ITCA 650 development program," said K. Alice Leung, President and CEO of Intarcia. "Within just 4 months of completing the phase 1b study, Intarcia began enrollment of an ongoing phase 2 study comparing ITCA 650 with twice-daily Byetta® (exenatide) injection among 150 patients with type 2 diabetes over a 3-month treatment period."

The phase 2 trial will evaluate ITCA 650 against the current standard of care for a longer duration of treatment and among a larger population of type 2 diabetes patients. The goals of the ITCA 650 program are to enhance the therapeutic effects of exenatide by ensuring patient compliance and providing more consistent, around-the-clock therapeutic drug levels, and to reduce side effects, including nausea associated with high peak levels of exenatide exposure observed with
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
2. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
3. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
4. Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes
5. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
6. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
7. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
8. Nile Therapeutics, Inc. Adds to Executive Management Team
9. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
10. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
11. Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... “We are honored to be named to ... CEO of Radiant Sage. “We are offering truly ground-breaking ... corelab market to a different level. We are ... efficiently and effectively manage the massive amounts of medical ... and read by trained physicians. Being recognized by technology ...
(Date:8/27/2014)... Reportbuyer.com has added a new market ... A Rational View https://www.reportbuyer.com/product/1595336/The-Graphene-Opportunity---A-Rational-View.html ... A similar amount of hype currently surrounds graphene, ... to water treatment, but is graphene the only ... Graphene Opportunity Report, authored by Tim Harper ...
(Date:8/27/2014)... Research and Markets has announced ... & Paper Industry Report 2014" report to their ... & Paper Industry Report 2014 is a professional and ... enzyme for pulp & paper industry. The ... definitions, classifications, applications and industry chain structure. The enzyme ...
(Date:8/27/2014)... , Aug. 27, 2014  ARCH Venture Partners, ... investing in the development of seed and early-stage ... venture fund closed with more than $400 million ... $250 million subscription target by more than $150 ... shows the strength and potential of our approach ...
Breaking Biology Technology:Radiant Sage Named to CIOReview List of 100 Most Promising Technology Companies 2The Graphene Opportunity - A Rational View 2The Graphene Opportunity - A Rational View 3The Graphene Opportunity - A Rational View 4Global Enzyme for Pulp & Paper Industry Report 2014 2Latest ARCH Venture Partners Fund Closes Above $400 Million 2Latest ARCH Venture Partners Fund Closes Above $400 Million 3
... Anticipating a catastrophic increase in Alzheimer,s disease and related ... Plan for Alzheimer,s disease, a disease estimated to double ... a 10-year course of action with guiding principles, goals ... crisis.   Alzheimer,s will soon soar to ...
... 2011 GlobalCare Clinical Trials, Ltd, (GlobalCare) today ... selected clinical study visits at convenient locations – ... – for study patients to support phase I-IV ... and personalized medicine in all age groups. GlobalCare,s ...
... Inc. (NYSE Amex: PTN ) announced that it ... Stock Conference on Tuesday, March 15, 2011, at 12:00 p.m. ... Carlton Laguna Niguel in Dana Point, CA. ... Technologies, will provide an update on Palatin,s corporate and development ...
Cached Biology Technology:California Leaders Confront Alarming Rise in Alzheimer's Cases 2California Leaders Confront Alarming Rise in Alzheimer's Cases 3GlobalCare Clinical Trials, Ltd Announces Company Expansion Into Latin America 2GlobalCare Clinical Trials, Ltd Announces Company Expansion Into Latin America 3GlobalCare Clinical Trials, Ltd Announces Company Expansion Into Latin America 4
(Date:8/27/2014)... manipulating neural circuits in the brain of mice, ... memories. The research, led by Howard Hughes Medical ... of Technology (MIT), reveals that the connections between ... information about an experience and the part of ... that experience are malleable. , Altering those ...
(Date:8/27/2014)... based upon a proxy for impact have been identified ... approach to scientific research. , The researchers from the ... top 100 pathogens affecting humans and the top 100 ... will help governments across the continent plan for risks ... a result of climate change, and for biosecurity. , ...
(Date:8/27/2014)... news release is available in German . ... 1A is the most common inherited disease affecting the ... at the Max Planck Institute of Experimental Medicine and ... of Schwann cells is impaired in rats with the ... insulating layer known as myelin, which facilitates the rapid ...
Breaking Biology News(10 mins):Researchers change the emotional association of memories 2Researchers change the emotional association of memories 3Researchers change the emotional association of memories 4Big data approach identifies Europe's most dangerous human and domestic animal pathogens 2Potential therapy for incurable Charcot-Marie-Tooth disease 2
... of researchers has shown that female kittens consume more food ... with entire littermates. This research was conducted at the WALTHAM ... Petcare brands such as WHISKAS and ROYAL CANIN. In ... consumed more food than their entire littermates for an 18 ...
... some strains of algae, when starved of nutrients, quickly build ... discovery lay dormant until people began to search in earnest ... 2000s, algal fuel production enjoyed a tremendous vogue, as scientists ... "pond scum" to oil. But a recent wave of bankruptcies ...
... October 2011, Christian Sonne, Senior Scientist at Aarhus University, defends ... University of Copenhagen. "The accumulated industrial chemicals cause diseases ... immediate deaths. On the other hand, the toxins damage the ... and not least their reproductive systems. However, the harm suffered ...
Cached Biology News:New research from WALTHAM demonstrates the importance of portion control for maintaining healthy body weight in neutered female kittens 2WUSTL wins $ 2.2 million US Department of Energy grant to build a fuel producing bacterium 2WUSTL wins $ 2.2 million US Department of Energy grant to build a fuel producing bacterium 3WUSTL wins $ 2.2 million US Department of Energy grant to build a fuel producing bacterium 4
... SDS and Non-ionic Detergent Removal ... detergent , Very selective, virtually no cross-reactivity ... centrifuge and discard pellet , Economical ... chromatography , Detergents can often interfere with ...
Extracti-Gel D Detergent Removing Gel...
Physical Form: saline suspension with ethanol Particle Dim: mean particle size 50 μm Matrix: HyperD F. Useful for the removal of detergents from protein samples....
SDS-OutT SDS Precipitation Reagent...
Biology Products: